Guardian Pharmacy Services, Inc. (GRDN)

NYSE: GRDN · USD

$40.4

+0.79 (+2.0%)· Recorded snapshot

Market cap	2.6B
Revenue (ttm)	1.5B
Net income (ttm)	65.9M
EPS (ttm)	$1.04
Shares out	63.3M
P/E (trailing)	39.0x
P/E (forward)	29.8x
Volume	173,013
Beta	0.02

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.5B
Net income (ttm): 65.9M
EPS (ttm): $1.04
P/E (trailing): 39.0x
P/E (forward): 29.8x
Market cap: 2.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E29.8

P25 n/aP50 n/aP75 n/a

Trailing P/E39

P25 n/aP50 n/aP75 n/a

ROE30.4

P25 n/aP50 n/aP75 n/a

ROIC28.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GRDN indicators

Market & fundamental data

Available fields

247

Groups with data

Currency

USD

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001802255
Company name	Guardian Pharmacy Services, Inc.
Country	United States
Country code	US
CUSIP number	40145W101
Earnings date	2026-11-05
Earnings time	amc
Employees	3,600
Employees change	200
Employees growth	5.88%
Enterprise value	$2.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
In index	RUSSELL2000
Industry	Medical Care Facilities
IPO date	2024-09-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US40145W1018
Last 10-K release date	2026-03-11
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.6B
Market cap category	Mid-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$40.35
Price currency	USD
Sector	Healthcare
SIC code	5912
Stock price date	2026-10-28
Symbol	GRDN
U.S. state	Georgia
Website	https://guardianpharmacy.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	33.63x
Earnings yield	2.57%
EV/Earnings	37.85x
EV/EBIT	28.99x
EV/EBITDA	22.8x
EV/FCF	31.27x
EV/Sales	1.7x
FCF / EV yield	3.2%
FCF yield	3.13%
Forward EV/Sales	1.68x
Forward P/E	29.77x
Forward P/S	1.71x
Graham number	9.50558
Graham upside	-76.34%
Industry forward P/E	15.38x
Industry P/E	18.76x
Lynch fair value	$25.89
Lynch upside	-35.57%
P/(FCF - SBC) ratio	36.59x
P/(OCF - SBC) ratio	28.72x
P/B ratio	10.2x
P/E ratio	38.97x
P/FCF ratio	31.9x
P/OCF ratio	25.75x
P/S ratio	1.74x
PEG ratio	1.8x
Price / tangible book value	17.05x
Price/EBITDA ratio	23.26x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	5.88%
EBITDA margin	7.48%
Effective tax rate	30.57%
FCF margin	5.45%
Gross margin	21.63%
Operating margin	5.88%
Pretax margin	6.55%
Profit margin	4.5%
Profit per employee	$18,308
Profitable quarters	7
Profitable years	1
Revenue per employee	$406,502
ROA	13.45%
ROA (5Y)	7.55%
ROCE	29.72%
ROE	30.42%
ROE (5Y)	27.67%
ROIC	28.73%
ROIC (5Y)	22.21%
SBC / revenue	0.7%
Tax / revenue	2%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	139.82%
EPS growth (QoQ)	64.15%
EPS growth quarters	4
EPS growth years	1
FCF growth	110.4%
FCF growth (Q)	62.55%
FCF growth (QoQ)	2,335.95%
FCF growth 3Y	20.67%
FCF growth 5Y	12.5%
Gross profit growth	21.54%
Gross profit growth (Q)	17.46%
Gross profit growth 3Y	16.72%
Gross profit growth 5Y	16.58%
Net income growth (Q)	142.22%
Net income growth (QoQ)	64.51%
Net income growth 3Y	41.23%
Net income growth 5Y	27.01%
Net income growth quarters	4
Net income growth years	1
OCF growth	71.45%
OCF growth (Q)	50.61%
OCF growth (QoQ)	395.3%
OCF growth 3Y	16.92%
OCF growth 5Y	13.44%
Operating income growth (Q)	-12.94%
Operating income growth 3Y	10.44%
Operating income growth 5Y	21.17%
Revenue growth	10.31%
Revenue growth (Q)	2.16%
Revenue growth (QoQ)	4.51%
Revenue growth 3Y	14.45%
Revenue growth 5Y	14.74%
Revenue growth quarters	9
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-19.1M
Depreciation and amortization	$23.4M
EBIT	$86M
EBITDA	$109.4M
EPS	$1.04
FCF per share	$1.26
Financing cash flow	$-5.1M
Free cash flow	$79.8M
Free cash flow minus SBC	$69.6M
Gross profit	$316.6M
Income taxes	$29.3M
Investing cash flow	$-22.7M
Net borrowing	$-4.9M
Net cash flow	$71M
Net income	$65.9M
Operating cash flow minus SBC	$88.6M
Operating income	$86M
Revenue	$1.5B
Stock-based compensation	$10.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	10.83
Book value per share	$3.88
Debt / EBITDA	0.32
Debt / equity	0.15
Debt / FCF	0.49
Goodwill	$79.7M
Interest coverage	136.36
Long-term assets	$188.9M
Long-term liabilities	$31.9M
Net cash (debt)	$50.5M
Net cash / market cap	1.99%
Net debt / EBITDA	-0.46
Net debt / equity	-0.2
Net debt / FCF	-0.63
Piotroski F-Score	6
Property, plant and equipment	$88.9M
Shareholders' equity	$257.6M
Tangible book value	$149.3M
Tangible book value per share	$2.36
Total assets	$443.6M
Total cash	$89.8M
Total debt	$39.3M
Total liabilities	$185.9M
WACC	4.33%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	3.66
Current assets	$254.7M
Current liabilities	$154M
Current ratio	1.65
Inventory turnover	24.25
Net working capital	$18.2M
Quick ratio	1.26
Working capital	$100.6M
Working capital turnover	23.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.91%
Dividend yield	0%
Shareholder yield	-1.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$39.76
1D price change	2%
1M price change	-2.43%
1M total return	-2.43%
1W price change	-3.96%
1W total return	-3.96%
1Y price change	38.42%
1Y return CAGR	38.45%
1Y total return	38.42%
20-day SMA	$40.45
200-day SMA	$37.98
3M price change	-3.01%
3M total return	-3.01%
50-day SMA	$40.94
50-day SMA vs 200-day SMA	50over200
52-week high	$48.33
52-week high date	2026-09-16
52-week low	$26.34
52-week low date	2026-01-20
6M price change	6.01%
6M total return	6.01%
All-time high	$48.33
All-time high date	2026-09-16
All-time low	$14.16
All-time low date	2024-09-26
Average true range (ATR)	$1.50
Average volume	391K
Beta (1Y)	0.31
Beta (2Y)	0.53
Beta (5Y)	0.02
Change from 52-week high	-16.51%
Change from 52-week low	53.19%
Change from all-time high	-16.8%
Change from all-time low	183.97%
Change from open	0.95%
Day's gap	1.04%
Dollar volume	$7M
High price	$40.41
Low price	$39.97
Monthly RSI	69.35
Open price	$39.97
Position in 52-week range	86.36%
Previous close	$39.56
Price vs 150-day SMA	1.13%
Price vs 20-day SMA	-0.6%
Price vs 200-day SMA	5.87%
Price vs 50-day SMA	-1.78%
Relative volume	0.44
Return from IPO open	177.87%
Return from IPO price	187%
RSI	48.14
Sharpe ratio	0.9
Sortino ratio	1.54
Volume	173K
Weekly RSI	52.43
YTD price change	33.63%
YTD total return	33.63%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.4M
Float percentage	35.33%
Shares change (QoQ)	0.22%
Shares change (YoY)	1.91%
Shares held by insiders	16.97%
Shares held by institutions	50.66%
Shares outstanding	63.3M
Short % of float	11.08%
Short % of shares	3.92%
Short ratio	3.5 days

Deeper analysis on GRDN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GRDN report

Is a complete GRDN research report available?

No complete published report is available for Guardian Pharmacy Services, Inc. (GRDN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Guardian Pharmacy Services, Inc. (GRDN)

Price

Financial snapshot

Fair-value bridge

Latest news · GRDN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GRDN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GRDN

Frequently asked questions